AstraZeneca Upbeat Internal Pipeline Can Drive Growth Beyond 2030

Dow Jones

Jul 28

0807 GMT - AstraZeneca struck an upbeat tone on its prospects through 2030 and beyond, signaling it doesn't need dealmaking to deliver growth into the next decade due to its pipeline, Berenberg analysts say in a research note. Executives at the U.K. drugmaker still expect clinical trials for which the company is due to report results this year to unlock more than $10 billion in combined annual peak sales, according to Berenberg. While its Wainua drug failed in a heart-disease study, higher-than-previously-expected sales potential for its respiratory medicine tozorakimab should make up for the shortfall, the analysts say. AstraZeneca now sees tozorakimab peak sales at more than $5 billion. Shares fall 1.7%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 28, 2026 04:08 ET (08:08 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2654747570"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2654747570\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2654747570?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 16:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654747570","market":"nz","top_or_hot":-1,"title":"AstraZeneca Upbeat Internal Pipeline Can Drive Growth Beyond 2030","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0807 GMT - AstraZeneca struck an upbeat tone on its prospects through 2030 and beyond, signaling it doesn't need dealmaking to deliver growth into the next decade due to its pipeline, Berenberg analysts say in a research note. Executives at the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker still expect clinical trials for which the company is due to report results this year to unlock more than $10 billion in combined annual peak sales, according to Berenberg. While its Wainua drug failed in a heart-disease study, higher-than-previously-expected sales potential for its respiratory medicine tozorakimab should make up for the shortfall, the analysts say. AstraZeneca now sees tozorakimab peak sales at more than $5 billion. Shares fall 1.7%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 28, 2026 04:08 ET (08:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Upbeat Internal Pipeline Can Drive Growth Beyond 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Upbeat Internal Pipeline Can Drive Growth Beyond 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-28 16:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0807 GMT - AstraZeneca struck an upbeat tone on its prospects through 2030 and beyond, signaling it doesn't need dealmaking to deliver growth into the next decade due to its pipeline, Berenberg analysts say in a research note. Executives at the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker still expect clinical trials for which the company is due to report results this year to unlock more than $10 billion in combined annual peak sales, according to Berenberg. While its Wainua drug failed in a heart-disease study, higher-than-previously-expected sales potential for its respiratory medicine tozorakimab should make up for the shortfall, the analysts say. AstraZeneca now sees tozorakimab peak sales at more than $5 billion. Shares fall 1.7%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 28, 2026 04:08 ET (08:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3T34201.USD","symbol_name":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2654747570","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654747570","pubTimestamp":1785226080,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0807 GMT - AstraZeneca struck an upbeat tone on its prospects through 2030 and beyond, signaling it doesn't need dealmaking to deliver growth into the next decade due to its pipeline, Berenberg analysts say in a research note. Executives at the U.K. drugmaker still expect clinical trials for which the company is due to report results this year to unlock more than $10 billion in combined annual peak sales, according to Berenberg. While its Wainua drug failed in a heart-disease study, higher-than-previously-expected sales potential for its respiratory medicine tozorakimab should make up for the shortfall, the analysts say. AstraZeneca now sees tozorakimab peak sales at more than $5 billion. Shares fall 1.7%.  Dow Jones NewswiresJuly 28, 2026 04:08 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4588":"碎股","BK4568":"美国抗疫概念","AZN":"阿斯利康","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","BK4007":"制药","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","AZNH":"ASTRAZENECA PLC ADRhedged","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","BK4585":"ETF&股票定投概念","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC"},"translate_title":"阿斯利康乐观地认为内部管道可以推动 2030 年以后的增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9,"AZNH":0.6},"content_text":"0807 GMT - AstraZeneca struck an upbeat tone on its prospects through 2030 and beyond, signaling it doesn't need dealmaking to deliver growth into the next decade due to its pipeline, Berenberg analysts say in a research note. Executives at the U.K. drugmaker still expect clinical trials for which the company is due to report results this year to unlock more than $10 billion in combined annual peak sales, according to Berenberg. While its Wainua drug failed in a heart-disease study, higher-than-previously-expected sales potential for its respiratory medicine tozorakimab should make up for the shortfall, the analysts say. AstraZeneca now sees tozorakimab peak sales at more than $5 billion. Shares fall 1.7%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 28, 2026 04:08 ET (08:08 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}